3
Disclosures
Jan 28, 2026 — Mar 24, 2026
Date Range
GROWTH
Market Segment

Disclosures

DateTypeHeadlinePDF
Mar 24 Other Oncolys BioPharma: Completes Key Milestones for OBP-301 and Telemerysin Stability Tests PDF
Mar 23 Other Oncolys BioPharma: Secures European Patent for OBP-601 Neurodegenerative Treatment PDF
Mar 19 Equity Issuance Oncolys BioPharma: Sees Revenue Drop Amid Strong Yen Impact PDF

Disclosure Types

Other: 2 Equity Issuance: 1